ORB-021
Oncology – Solid Tumors
Key Facts
About Orionis Biosciences
Orionis Biosciences is a private, clinical-stage biotech founded in 2015, focused on creating next-generation cancer therapies through its three core technology platforms: Allo-Glue™ for molecular glues, A-Kine® for conditionally active cytokines, and multimodal cell engagers (MCEs). The company has advanced two A-Kine® candidates, ORB-011 and ORB-021, into Phase 1 clinical trials for solid tumors and has secured significant strategic partnerships with industry leaders like Genentech and Novartis. Orionis operates as a platform/therapeutics company, currently in a pre-revenue stage, with a strategy centered on advancing its internal pipeline while leveraging collaborations to expand the application of its disruptive technologies.
View full company profileTherapeutic Areas
Other Oncology – Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| ORB-011 | Orionis Biosciences | Phase 1 |